Abiopharma

🔍 Glaser Shelagh (Executive)

Company: SYNOPSYS INC (SNPS)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 1,259 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,888.00 | transaction_form_type: 4
• Sold 436 shares of Common Stock at $454.38 per share (Direct)
  Date: 2026-06-15 | Code: F | equity_swap_involved: 0 | shares_owned_after: 1,452.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: by Trust | shares_owned_after: 14,358.00
• Sold 1,259 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | Expires: 2028-12-15 | Exercise: 2026-06-15 | equity_swap_involved: 0 | shares_owned_after: 6,295.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: These shares were retained by the Company in order to meet the tax withholding obligations of the reporting person in connection with the vesting of an installment of the restricted stock unit award. The Compensation Committee approved the disposition of shares by the reporting person and the amount retained by the Company was not in excess of the amount of the tax liability.
• F2: Each stock unit converts into one share of Synopsys common stock.
• F3: One-sixth (1/6) of the units vest on the date shown followed by five equal semi-annual installments, subject to continued service through each vesting date.